Point-of-care genetic testing
Point-of-care genetic testing incorporates the newest most sophisticated techniques to identify variations in the genetic sequence at the bedside – enabling clinicians to react and alter therapy based upon the results.
Traditional genetic testing involves the analysis of DNA in order to detect genotypes related to a heritable disease or phenotype of interest for clinical purposes. However, current testing methods require days to weeks before results are available limiting the clinical applicability of genetic testing in a number of circumstances.
Recently, the first point-of-care genetic test in medicine was demonstrated to be effective in identifying CYP2C19*2 carriers allowing tailoring of anti-platelet regimens to reduce high on treatment platelet reactivity.[1] In the RAPID GENE study,[2] Drs. Jason Roberts and Derek So from the University of Ottawa Heart Institute validated a pharmacogenomics approach in patients undergoing percutaneous coronary intervention for acute coronary syndrome or stable coronary artery disease.[3][4][5]
This study is the first in medicine to incorporate point-of-care testing with genetics into routine clinical care and decision making.[6]
References
- ↑ http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2960161-5/abstract#
- ↑ http://clinicaltrials.gov/ct2/show/NCT01184300
- ↑ http://www.winnipegfreepress.com/arts-and-life/life/health/first-bedside-gene-test-shows-promise-144912695.html
- ↑ http://www.theglobeandmail.com/life/health/new-health/conditions/heart-and-stroke/treatment/new-bedside-genetic-tests-pick-the-right-drug-right-away/article2393347/
- ↑ http://blogs.theheart.org/topolog/2012/4/11/taking-pointofcare-genetic-testing-closer-to-mainstream?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Topolog+%28Topolog%29
- ↑ http://clinicaltrialresults.org/Slides/TCT%202011/So%20Late%20breaking%20Trial%20RAPID%20GENE%20TCT%20web%20site%20version.pdf